Innoviva
INVA · Nasdaq · United States
Share price · INVA
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when INVA's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 5 Nov 2026-9.5%
- 23 Sep 2026-3.5%
Nothing announced by INVA that day or the session before.
- 7 Aug 2026-2.8%
Nothing announced by INVA that day or the session before.
- 1 Jul 2026-3.6%
Nothing announced by INVA that day or the session before.
- 11 Jun 2026-2.4%
Nothing announced by INVA that day or the session before.
- 10 Jun 2026+2.0%
Nothing announced by INVA that day or the session before.
- 27 May 2026-2.4%
Nothing announced by INVA that day or the session before.
- 15 May 2026-3.9%
Nothing announced by INVA that day or the session before.
- 25 Feb 2026+3.5%
Nothing announced by INVA that day or the session before.
- 17 Feb 2026+5.1%
Nothing announced by INVA that day or the session before.
Share of unusual movement by asset
For each asset, the share of INVA's own-move activity since 14 Oct 2025 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
| Other company news (earnings, financing, releases naming no asset) | — | 9% |
| Sessions with no dated event | — | 91% |
No dated announcements about its assets since 14 Oct 2025.
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Approved | Muscarinic acetylcholine receptor (M3) · Beta-2 adrenergic receptorSmall molecule | Chronic Obstructive Pulmonary Disease |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Financial reports
Quarterly & interim (15)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $106M | $5.2M | $581M | $74M$42M operating cash flow | report ↗ |
View 14 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $120M | $5.2M | $570M | $83M$52M operating cash flow | report ↗ |
| 2026-Q1 | $98M | $5.2M | $603M | —$35M operating cash flow | report ↗ |
| 2025-Q3 | $108M | $14M | $477M | —$50M operating cash flow | report ↗ |
| 2025-Q2 | $100M | $8.0M | $398M | —$44M operating cash flow | report ↗ |
| 2025-Q1 | $89M | $4.4M | $319M | $47M$49M operating cash flow | report ↗ |
| 2024-Q3 | $90M | $3.5M | $261M | —$49M operating cash flow | report ↗ |
| 2024-Q2 | $100M | $2.6M | $217M | $35M$44M operating cash flow | report ↗ |
| 2024-Q1 | $78M | $3.9M | $178M | —$37M operating cash flow | report ↗ |
| 2023-Q3 | $67M | $4.0M | $180M | —$44M operating cash flow | report ↗ |
| 2023-Q2 | $81M | $15M | $173M | —$38M operating cash flow | report ↗ |
| 2023-Q1 | $76M | $13M | $144M | —$26M operating cash flow | report ↗ |
| 2022-Q3 | $67M | $12M | $301M+ $0.3M short-term inv. | —$16M operating cash flow | report ↗ |
| 2022-Q2 | $108M | $14M | $284M | —$79M operating cash flow | report ↗ |
| 2022-Q1 | $90M | $5.8M | $217M | —$98M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $411M | $31M | $551M | —$197M operating cash flow | report ↗ |
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $359M | $14M | $305M | —$189M operating cash flow | report ↗ |
| 2023-FY | $310M | $34M | $194M | —$141M operating cash flow | report ↗ |
| 2022-FY | $331M | $41M | $291M | —$202M operating cash flow | report ↗ |
| 2021-FY | $392M | $0.6M | $202M+ $0 short-term inv. | —$364M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-08-20 | Raifeld Pavel · director, Chief Executive Officer | Tax withholding | 1,130 | $21.00 | $24K | Form 4 |
| 2026-08-20 | Basso Stephen · Chief Financial Officer | Tax withholding | 558 | $21.00 | $12K | Form 4 |
| 2026-08-20 | Zhen Marianne · Chief Accounting Officer | Tax withholding | 1,127 | $21.00 | $24K | Form 4 |
| 2026-05-20 | Zhen Marianne · Chief Accounting Officer | Tax withholding | 1,127 | $22.24 | $25K | Form 4 |
| 2026-05-20 | Raifeld Pavel · director, Chief Executive Officer | Tax withholding | 1,130 | $22.24 | $25K | Form 4 |
| 2026-05-20 | Basso Stephen · Chief Financial Officer | Tax withholding | 559 | $22.24 | $12K | Form 4 |
| 2026-05-18 | Linden Josephine · director | Award / grant | 5,733 | — | — | Form 4 |
| 2026-05-18 | Linden Josephine · director | Award / grant | 9,461 | — | — | Form 4 |